Ncardia (Evotec) specializes in leveraging human induced pluripotent stem cell (iPSC) technology to enhance drug discovery and development processes. With over a decade of experience, the company provides a comprehensive suite of services that includes high-quality cell supply, custom iPSC services, and robust screening assays. Their expertise allows for the differentiation of iPSCs into various functional cell types, which are essential for modeling diseases and testing therapeutic candidates. Ncardia's integrated iPSC solutions are designed to support therapeutic developers in making informed decisions early in the drug development pipeline, ultimately aiming to accelerate the delivery of new therapies to patients.

The company emphasizes the importance of translational assays that replicate human biology, thereby increasing the predictive power of drug discovery efforts. Ncardia's offerings include disease-relevant screening assays, patient-derived models, and advanced automation capabilities to streamline the research process. Their commitment to quality and reproducibility is evident in their rigorous characterization of cell lines and the development of customized assays tailored to specific research needs. By combining deep iPSC knowledge with a focus on customer service, Ncardia positions itself as a trusted partner for pharmaceutical companies seeking to mitigate risks and enhance the success of their therapeutic projects.

Belgium

Ncardia's hiPSC products portfolio encompasses a broad panel of cardiovascular and neural cells. In addition, the company delivers the Cardioplate™ product line of quality-controlled ready-to-use assay plates.

Ncardia (Evotec)

Company Details